258 related articles for article (PubMed ID: 38495287)
1. Metabolic-associated fatty liver disease and sarcopenia: A double whammy.
Viswanath A; Fouda S; Fernandez CJ; Pappachan JM
World J Hepatol; 2024 Feb; 16(2):152-163. PubMed ID: 38495287
[TBL] [Abstract][Full Text] [Related]
2. Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge.
Fouda S; Pappachan JM
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):xv-xvi. PubMed ID: 37495346
[TBL] [Abstract][Full Text] [Related]
3. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study.
Zhao Q; Yin Y; Deng Y
Nutr Diabetes; 2023 Nov; 13(1):21. PubMed ID: 37968264
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
5. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-Associated Fatty Liver Disease and Sarcopenia.
Bali T; Chrysavgis L; Cholongitas E
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):497-508. PubMed ID: 37495340
[TBL] [Abstract][Full Text] [Related]
7. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
8. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Lee H; Lim TS; Kim SU; Kim HC
Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
[TBL] [Abstract][Full Text] [Related]
9. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
10. Metabolic puzzle: Exploring liver fibrosis differences in Asian metabolic-associated fatty liver disease subtypes.
Shaikh SS; Qazi-Arisar FA; Nafay S; Zaheer S; Shaikh H; Azam Z
World J Hepatol; 2024 Jan; 16(1):54-64. PubMed ID: 38313248
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.
Fernandez CJ; Alkhalifah M; Afsar H; Pappachan JM
Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251375
[TBL] [Abstract][Full Text] [Related]
14. Metabolic-Associated Fatty Liver Disease and Diabetes: A Double Whammy.
Kapoor N; Kalra S
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):469-484. PubMed ID: 37495338
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
[TBL] [Abstract][Full Text] [Related]
16. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
19. Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks.
Barber TM; Kabisch S; Pfeiffer AFH; Weickert MO
Metabolites; 2023 Jun; 13(6):. PubMed ID: 37367914
[TBL] [Abstract][Full Text] [Related]
20. Pathobiology of Metabolic-Associated Fatty Liver Disease.
Fouda S; Jeeyavudeen MS; Pappachan JM; Jayanthi V
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):405-416. PubMed ID: 37495333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
